Search the evidence, not the hype.

A prescription peptide medicine with established uses, product-specific labels, and an important divide between approved and unapproved versions.

A natural peptide hormone and foundational family of diabetes medicines whose effects, risks, and use depend on the exact product and care plan.

A dual GIP and GLP-1 receptor agonist with approved products and large human trials, bounded by product-specific indications, labels, and safety information.

An investigational peptide with a sizable preclinical literature, early human work, and a large gap between biological signal and proven clinical effect.

A long-acting growth-hormone-releasing hormone analogue with clear human biomarker activity but no established clinical benefit for popular body-composition or recovery claims.

A growth-hormone secretagogue with demonstrated human pharmacology, a negative proof-of-concept efficacy trial, and unresolved route, safety, and product-quality questions.

An established GLP-1 medicine whose evidence belongs to specific products, indications, populations, and current labels.

A triple-receptor investigational peptide with meaningful late-stage human results but no approved product or completed regulatory review.

An approved GHRF analogue for a specific HIV-associated body-composition outcome, not a general weight-loss or anti-aging medicine.

A GHRH fragment with historical approvals and real hormone-release pharmacology, but no current approved product and no established anti-aging outcome evidence.

A seven-amino-acid thymosin fragment promoted for repair despite an unresolved human-outcome gap, significant product questions, and anti-doping prohibition.

A copper-binding tripeptide with topical and laboratory research that does not validate injectable, whole-body, or longevity claims.

A mitochondria-derived peptide with active preclinical research but no established human drug-product outcomes or adequate clinical safety record.

A modified growth-hormone fragment studied in obesity programs without an approved use and with unresolved route, product, and safety questions.

A tetrapeptide promoted for sleep and longevity despite identity transfer problems and no established insomnia or lifespan outcome evidence.

An approved melanocortin medicine for a defined sexual-desire disorder, not a general sexual-performance enhancer.

An approved implant that increases pain-free light exposure in adults with EPP, not a general-purpose tanning or cosmetic peptide.

An established bone-anabolic peptide medicine with fracture-prevention evidence that should not be generalized to every healing claim.

An approved bone-anabolic peptide with fracture outcome evidence in defined osteoporosis populations and product-specific safety limits.

An established GLP-2 medicine that can reduce parenteral-support needs in short bowel syndrome, with intensive product-specific monitoring.